<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376660</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1205</org_study_id>
    <nct_id>NCT02376660</nct_id>
  </id_info>
  <brief_title>Effect of Oats on Lipid Profile</brief_title>
  <official_title>A Randomized Controlled Trial to Evaluate the Efficacy of 3 g of Soluble Fiber From Oats on the Lipid Profile of Men and Women With Elevated Lipid Levels Aged Between 20 and 50 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized control trial to assess the effect of oats on lipid profile of mildly&#xD;
      hypercholesterolemic subjects. Subjects consumed 35g of oats twice daily (total of 70g / day)&#xD;
      in place of carbohydrates as part of their usual diet. 70 grams of oats provide 3 grams of&#xD;
      soluble fiber. Control group consumed the usual diet. Subjects followed up for 4 weeks. In&#xD;
      total 3 assessment visits of the subjects planned for the study period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of total cholesterol</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL-c</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Mildly Hypercholesterolemic Subjects</condition>
  <arm_group>
    <arm_group_label>Oats</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70 grams oats</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual diet and exercise</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>usual diet and exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oats</intervention_name>
    <arm_group_label>Oats</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women between 20 and 50 years old&#xD;
&#xD;
          -  Total Cholesterol: â‰¥ 200 mg/dL and &lt; 240mg/dL&#xD;
&#xD;
          -  Availability and willingness to follow study protocol&#xD;
&#xD;
          -  Stable body weight for previous 3 months (not more than 5% weight change)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects already on lipid lowering drugs&#xD;
&#xD;
          -  LDL-c &gt; 190 mg/dL&#xD;
&#xD;
          -  Total cholesterol &lt;200 mg/dL and &gt;240 mg/dL&#xD;
&#xD;
          -  Subjects with serum creatinine levels &gt; 1.3 mg/dL (female) or 1.4 mg/dL (male),&#xD;
             nephropathy, evidence of hepatic disease or history of alcohol abuse&#xD;
&#xD;
          -  Baseline Triglycerides: &gt; 300 mg/dL&#xD;
&#xD;
          -  Diabetes (Type 1 or Type 2) as diagnosed by a physician&#xD;
&#xD;
          -  Uncontrolled hyperthyroidism (as per physician's discretion)&#xD;
&#xD;
          -  Uncontrolled hypertension (as per physician's discretion)&#xD;
&#xD;
          -  Acute infections or chronic debilitating diseases like tuberculosis, malignancy, HIV&#xD;
             infection etc. Any life threatening serious disorder of the liver, kidneys, heart,&#xD;
             lungs or other organs by history&#xD;
&#xD;
          -  Irritable bowel syndrome by history&#xD;
&#xD;
          -  Unwillingness to give written informed consent for participation in the study.&#xD;
&#xD;
          -  Pregnancy &amp; lactation (by history)&#xD;
&#xD;
          -  Severe end organ damage&#xD;
&#xD;
          -  Subjects with allergy to oats&#xD;
&#xD;
          -  Heavy smokers (smoking more than 5 cigarettes per day)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anoop Misra, MD, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fortis Clinical Research Limited</affiliation>
  </overall_official>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>February 25, 2015</last_update_submitted>
  <last_update_submitted_qc>February 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

